08:14 AM EDT, 10/08/2025 (MT Newswires) -- Aquestive Therapeutics ( AQST ) said Wednesday that it received two additional patents from the US Patent and Trademark Office for its Anaphylm sublingual film.

The patents feature formulations that include prodrugs of epinephrine and other components designed to facilitate oral mucosal absorption via film, the company said.

Both patents are set to expire on May 4, 2037, subject to any extensions, it said.

If approved by the FDA, the sublingual film will become the first and only medication to treat severe allergic reactions, including anaphylaxis, the company said.

Aquestive Therapeutics ( AQST ) also said that a Prescription Drug User Fee Act target action date for Anaphylm is scheduled for Jan. 31, 2026.